v3.25.2
Debt (Additional Information) (Details)
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Dec. 31, 2025
USD ($)
Sep. 30, 2025
USD ($)
Feb. 28, 2025
USD ($)
Days
Jan. 02, 2025
USD ($)
shares
Dec. 21, 2024
USD ($)
Oct. 08, 2024
USD ($)
$ / shares
shares
Sep. 23, 2024
USD ($)
Sep. 21, 2023
USD ($)
Sep. 30, 2023
USD ($)
Mar. 31, 2024
Jun. 30, 2025
USD ($)
$ / shares
shares
Jun. 30, 2024
USD ($)
shares
Dec. 31, 2026
USD ($)
Dec. 31, 2025
USD ($)
Dec. 31, 2024
USD ($)
shares
Jul. 22, 2025
$ / shares
shares
Oct. 31, 2024
shares
Sep. 20, 2024
USD ($)
Jun. 18, 2024
shares
Debt Instrument [Line Items]                                      
Net cash proceeds for direct offering                     $ 7,000,000                
Purchased revenue liability, current                     4,590,000       $ 4,115,000        
Repayment of debt prinnciple installment                     0 $ 35,000,000              
Debt, current                     $ 39,871,000       $ 34,876,000        
Ordinary shares issued | shares                     6,955,694       6,951,622       3,250,000
Amortization payment       $ 1,100,000                              
Warrants exercised price | $ / shares                     $ 36.4                
Purchased revenue liability                     $ 7,600,000       $ 6,800,000        
Senior Notes [Member]                                      
Debt Instrument [Line Items]                                      
Principle amount of issued debt                 $ 101,900,000                    
Net cash proceeds for direct offering                     9,578,835,000                
Repayment of debt prinnciple installment         $ 15,000,000,000                            
Estimated fair value                     18,500,000       12,200,000        
Debt, current                     18,500,000       12,200,000        
Repurchase of warrants                     $ 300,000                
Date of Maturity Start                     Sep. 23, 2024                
Maturity Date End                     Sep. 30, 2024                
Debt maturity date           Sep. 23, 2024 Mar. 21, 2025                        
Amortization payment             $ 1,700,000                        
Payment to Oramed                                   $ 2,000,000  
Maturity Date           Sep. 23, 2024 Mar. 21, 2025                        
Senior Notes [Member] | Maximum [Member]                                      
Debt Instrument [Line Items]                                      
Amortization payment                     $ 20,000,000                
Senior Notes [Member] | Minimum [Member]                                      
Debt Instrument [Line Items]                                      
Amortization payment                     0                
Deferral and Consent under Tranche B Senior Secured Convertible Note [Member]                                      
Debt Instrument [Line Items]                                      
Debt principal amount       $ 6,250,000                              
Redemption Premium       100.00%                              
Securities Purchase Agreement | First installment [Member]                                      
Debt Instrument [Line Items]                                      
Repayment of debt prinnciple installment               $ 5,000,000                      
Securities Purchase Agreement | Second Installment [Member]                                      
Debt Instrument [Line Items]                                      
Repayment of debt prinnciple installment               15,000,000                      
Securities Purchase Agreement | Third Installment [Member]                                      
Debt Instrument [Line Items]                                      
Repayment of debt prinnciple installment               20,000,000                      
Securities Purchase Agreement | Senior Notes [Member]                                      
Debt Instrument [Line Items]                                      
Principle amount of issued debt               101,900,000                      
Debt instrument, description                   Interest under the Oramed Note accrues at a fluctuating per annum interest rate equal to the sum of (1) the greater of (x) 4% and (y) Term SOFR (as defined in the Oramed Note) and (2) 8.5%, payable in-kind on a monthly basis. Pursuant to the Oramed Note, since the outstanding principal of the Oramed Note was not repaid in full on or prior to March 21, 2024, an exit fee of approximately $3.1 million has been earned with respect to the Oramed Note, which shall be due and payable on the date on which the outstanding principal amount of the Oramed Note is paid in full. Upon the occurrence and during the continuance of an event of default under the Oramed Note, holders of more than 50% of the aggregate unpaid principal amount of the Oramed Notes may elect to accrue interest at a default rate equal to the lesser of (i) Term SOFR plus 15% or (ii) the maximum rate permitted under applicable law. Voluntary prepayments made before the one-year anniversary of the closing date of the Scilex-Oramed SPA must include a make-whole amount equal to 50% of the additional interest that would accrue on the principal amount so prepaid from the date of such prepayment through and including the maturity date. If the Oramed Note is accelerated upon an event of default, repayment is required at a mandatory default rate of 125% of the principal amount (together with 100% of accrued and unpaid interest thereon and all other amounts due in respect of the Oramed Note). The Oramed Note contains mandatory prepayment provisions requiring use of 70% of net cash proceeds from any Cash Sweep Financing (as defined in the Oramed Note) or advances under the ELOCs (as defined in the Oramed Note) to prepay the outstanding principal after the earlier of April 1, 2024 or full repayment of Acceptable Indebtedness (as defined in the Oramed Note).                  
Debt Repayment Exit Fee               $ 3,100,000                      
Debt instrument, interest rate               4.00%                      
Debt maturity date               Mar. 21, 2025                      
Debt instrument, owned, percentage               50.00%                      
Debt instrument, default interest rate               15.00%                      
Debt instrument, percentage of interest accrued on principal amount               50.00%                      
Debt repayment, percentage of mandatory default rate of principal amount               125.00%                      
Debt repayment, percentage of mandatory default rate of accrued and unpaid interest               100.00%                      
Percentage of usage of cash proceeds from cash sweep financing               70.00%                      
Maturity Date               Mar. 21, 2025                      
Securities Purchase Agreement | Senior Notes [Member] | Monthly Basis [Member]                                      
Debt Instrument [Line Items]                                      
Debt instrument, interest rate               8.50%                      
Securities Purchase Agreement | Senior Notes [Member] | First installment [Member]                                      
Debt Instrument [Line Items]                                      
Debt maturity date               Mar. 21, 2025                      
Maturity Date               Mar. 21, 2025                      
Securities Purchase Agreement | Senior Notes [Member] | Second Installment [Member]                                      
Debt Instrument [Line Items]                                      
Debt maturity date               Dec. 21, 2023                      
Maturity Date               Dec. 21, 2023                      
Securities Purchase Agreement | Senior Notes [Member] | Third Installment [Member]                                      
Debt Instrument [Line Items]                                      
Debt maturity date               Mar. 21, 2024                      
Maturity Date               Mar. 21, 2024                      
Securities Purchase Agreement | Senior Notes [Member] | Fourth Installment [Member]                                      
Debt Instrument [Line Items]                                      
Debt maturity date               Jun. 21, 2024                      
Maturity Date               Jun. 21, 2024                      
Securities Purchase Agreement | Senior Notes [Member] | Five Installment [Member]                                      
Debt Instrument [Line Items]                                      
Debt maturity date               Sep. 21, 2024                      
Maturity Date               Sep. 21, 2024                      
Securities Purchase Agreement | Senior Notes [Member] | Six Installment [Member]                                      
Debt Instrument [Line Items]                                      
Debt maturity date               Dec. 21, 2024                      
Maturity Date               Dec. 21, 2024                      
Gloperba-Elyxyb Royalty Purchase Agreement [Member]                                      
Debt Instrument [Line Items]                                      
Percentage of aggregate net sales     4.00%                                
No of Calendar Days | Days     60                                
Royalty Purchase Agreement [Member]                                      
Debt Instrument [Line Items]                                      
Purchased revenue liability     $ 500,000               600,000                
Tranche Note [Member]                                      
Debt Instrument [Line Items]                                      
Ordinary shares issued | shares           62,794                     104,848    
Subsequent Event [Member]                                      
Debt Instrument [Line Items]                                      
Repayment of debt prinnciple installment                         $ 19,200,000 $ 14,100,000          
Ordinary shares issued | shares                               1,390,443      
Warrants exercised price | $ / shares                               $ 40      
Subsequent Event [Member] | Tranche Note [Member]                                      
Debt Instrument [Line Items]                                      
Warrants exercised price | $ / shares                               $ 36.4      
ATM Sales Agreement [Member]                                      
Debt Instrument [Line Items]                                      
Net cash proceeds for direct offering                     $ 1,760,796                
Ordinary shares issued | shares                     0 2,637              
Oramed Letter Agreement                                      
Debt Instrument [Line Items]                                      
Warrants execiseable | shares                     114,286                
Aggregate purchase of private placement warrants (in Shares) | shares                     114,286                
Oramed Letter Agreement | Senior Notes [Member]                                      
Debt Instrument [Line Items]                                      
Warrant Purchase | shares                     4,000,000                
Oramed [Member] | Subsequent Event [Member]                                      
Debt Instrument [Line Items]                                      
Repurchase of warrants $ 14,000,000 $ 13,000,000                                  
Scilex Pharma [Member]                                      
Debt Instrument [Line Items]                                      
Total number of shares granted | shares       142,855                              
Scilex Pharma [Member] | Royalty Purchase Agreement [Member]                                      
Debt Instrument [Line Items]                                      
Federal funds purchased, average rate paid           8.00%                          
Scilex Pharma [Member] | Royalty Purchase Agreement [Member] | Senior Notes [Member]                                      
Debt Instrument [Line Items]                                      
Amount extinguished and reduced           $ 2,500,000                          
Amount paid for purchased receivables           2,500,000                          
ZTlido Royalty [Member]                                      
Debt Instrument [Line Items]                                      
Purchased revenue liability, current     $ 600,000               $ 500,000                
Common Stock [Member]                                      
Debt Instrument [Line Items]                                      
Shares Delivered | shares                     92,857                
Common Stock [Member] | Tranche Note [Member]                                      
Debt Instrument [Line Items]                                      
Fair value of common shares                     $ 2,200,000                
Common Stock [Member] | Oramed [Member]                                      
Debt Instrument [Line Items]                                      
Fair value of common shares                     1,400,000                
Senior Secured Convertible Notes [Member]                                      
Debt Instrument [Line Items]                                      
Debt Instrument, Periodic Payment           12,500,000,000                          
Senior Secured Convertible Notes [Member] | Securities Purchase Agreement                                      
Debt Instrument [Line Items]                                      
Financing Receivable, Purchased with Credit Deterioration, Amount at Purchase Price, Total           5,000,000                          
Purchase price for the purchased receivables           5,000,000                          
Proceeds received from purchase agreement           $ 50,000,000                          
Conversion Price | $ / shares           $ 36.4                          
Loss in changes in fair value                             2,600,000        
Senior Secured Convertible Notes [Member] | Royalty Purchase Agreement [Member]                                      
Debt Instrument [Line Items]                                      
Purchased revenue liability, current                     $ 7,000,000       6,800,000        
Payments of debt issuance costs                             $ 200,000        
Senior Secured Convertible Notes [Member] | Oramed [Member] | Securities Purchase Agreement | Principal Balance [Member]                                      
Debt Instrument [Line Items]                                      
Reduction of the principal balance           $ 22,500,000                          
Senior Secured Convertible Notes [Member] | Scilex Pharma [Member] | Royalty Purchase Agreement [Member]                                      
Debt Instrument [Line Items]                                      
Financing Receivable, Purchased with Credit Deterioration, Amount at Purchase Price, Total           5,000,000                          
Paid to royalty investors           2,500,000                          
Purchase price for the purchased receivables           $ 5,000,000                          
Senior Secured Convertible Notes [Member] | October Common Warrants [Member]                                      
Debt Instrument [Line Items]                                      
Warrants exercised price | $ / shares           $ 36.4                          
Senior Secured Convertible Notes [Member] | October Common Warrants [Member] | Investor Agreement [Member]                                      
Debt Instrument [Line Items]                                      
Ordinary shares issued | shares           107,142                          
Senior Secured Convertible Notes [Member] | October Common Warrants [Member] | Oramed [Member] | Investor Agreement [Member]                                      
Debt Instrument [Line Items]                                      
Ordinary shares issued | shares           107,142                          
Senior Secured Convertible Notes [Member] | Common Stock [Member] | Investor Agreement [Member]                                      
Debt Instrument [Line Items]                                      
Debt Instrument Repurchased Face Amount           $ 22,500,000                          
Senior Secured Convertible Notes [Member] | Common Stock [Member] | October Common Warrants [Member] | Securities Purchase Agreement                                      
Debt Instrument [Line Items]                                      
Warrants execiseable | shares           214,284                          
Aggregate purchase of private placement warrants (in Shares) | shares           214,284